Stock Report

Download full stock data and analysis for free Last Updated: 27-Aug-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Glenmark Pharmaceuticals Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: GLENMARK | BSE: 532296

₹2,448.10

up-down-arrow ₹9.80 (0.40%)

As on 27-Aug-2026 14:44IST

Market cap

info icon

₹69,347 Cr

Revenue (TTM)

info icon

₹17,737 Cr

P/E Ratio

info icon

38.6

P/B Ratio

info icon

6.3

Div. Yield

info icon

0.1 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 6.57 23.10 32.94 13.42 8.93
EBIT 2.75 40.18 126.49 51.01 19.21
Net Profit -18.38 135.13 174.54 122.36 25.13
EPS 60.22 930.33 138.54 91.83 11.94
Book Value -- -- 18.52 3.48 8.27
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-26Mar-25
EBIT-Margin info 15.0313.3723.5723.5514.00
Net Margin info 23.891.679.867.817.79
Return on equity info 10.423.3730.8714.1012.56
Return on Capital info 13.6212.00--20.3516.16
Return on Assets info 7.381.9710.008.117.42
Debt to Equity (x) info ----0.000.000.25

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
--
20.35
16.16
4.88
4.43
Peer Median
--
16.42
14.72
18.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

30.87

Higher than Peers by 20.01

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
30.87
14.10
12.56
-21.18
-0.97
Peer Median
10.86
14.10
11.67
14.92
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

10.00

Higher than Peers by 3.26

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
10.00
8.11
7.42
-11.86
-0.54
Peer Median
6.74
8.20
7.86
9.06
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

23.57

Higher than Peers by 10.88

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
23.57
23.55
14.00
5.19
9.20
Peer Median
12.69
14.78
15.03
14.71
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

9.86

Higher than Peers by 1.00

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
9.86
7.81
7.79
-14.47
-0.75
Peer Median
8.86
8.55
9.33
8.49
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
--
5.59
5.34
-4.51
1.70
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

32.94

Higher than Peers by 24.80

Year on year growth in net sales

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
32.94
27.48
12.77
1.98
-5.86
Peer Median
8.14
14.12
10.27
11.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

126.49

Higher than Peers by 109.25

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
126.49
114.38
204.09
-42.45
-41.87
Peer Median
17.24
21.59
24.15
28.00
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

174.54

Higher than Peers by 157.68

Year on year growth in profit after tax

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
174.54
30.06
157.19
-1,944.25
-109.01
Peer Median
16.85
28.31
30.29
36.51
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

138.54

Higher than Peers by 127.94

Year on year growth in earnings per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
138.54
30.06
169.73
-605.16
-68.44
Peer Median
10.60
14.25
24.50
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
--
18.53
12.91
-17.20
4.26
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
--
--
0.25
0.13
0.46
Peer Median
0.04
0.20
0.23
0.20
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
--
--
0.19
0.11
0.04
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

1.77

Higher than Peers by 0.05

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
1.77
1.77
1.56
1.28
1.85
Peer Median
1.72
1.83
1.79
1.96
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

1.23

Higher than Peers by 0.06

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
1.23
1.23
1.05
0.84
1.33
Peer Median
1.17
1.23
1.47
1.44
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

13.38

Higher than Peers by 5.52

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
13.38
10.51
7.76
1.07
1.69
Peer Median
7.86
8.44
9.42
8.58
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

27.98

Higher than Peers by 2.20

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
27.98
29.23
25.09
15.73
31.64
Peer Median
25.79
25.29
25.82
26.12
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.99

Higher than Peers by 0.32

Sales / Average Total Assets

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
0.99
2.06
2.03
1.79
1.71
Peer Median
0.67
0.73
0.75
0.77
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
--
43.78
33.06
36.38
43.76
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
--
34.05
35.23
32.19
31.52
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
--
264.58
237.83
190.23
186.18
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
--
-186.74
-169.54
-121.67
-110.90
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

38.57

Lower than Peers by 1.59

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
38.57
44.21
41.50
--
44.14
Peer Median
40.16
40.16
39.70
33.48
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

6.33

Higher than Peers by 2.17

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
6.33
5.75
4.92
3.45
1.39
Peer Median
4.16
4.19
3.72
4.21
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

0.10

Lower than Peers by 0.00

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
0.10
0.12
0.16
0.26
0.54
Peer Median
0.11
0.11
0.16
0.21
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

12.87

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
12.87
11.73
17.83
12.95
8.48
Peer Median
--
28.43
30.23
29.90
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

69,347

Higher than Peers by 61,752

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Glenmark Pharmaceuticals
69,347
60,201
43,458
27,020
13,120
Peer Median
7,594
5,908
4,851
2,099
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...